Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multi-center extension to the advance trial

被引：0
|
作者：
Klein, B. [1 ]
Miceli, R. [2 ]
Severt, L. [2 ]
McAllister, P. [3 ]
Mechtler, L. [4 ]
McVige, J. [4 ]
Diamond, M. [5 ]
Marmura, M. J. [6 ]
Guo, H. [2 ]
Finnegan, M. [2 ]
Trugman, J. M. [2 ]
机构：
[1] Abington Neurol Associates Ltd, Abington, PA USA
[2] AbbVie, Madison, NJ USA
[3] New England Inst Neurol & Headache, Stamford, CT USA
[4] DENT Neurol Inst, Amherst, NY USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
[6] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL077
引用
收藏
页码：235 / 235
页数：1
相关论文
共 34 条
  • [21] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, R.
    Madonia, J.
    Hould, J.
    Mosher, L.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [22] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, Robert
    Madonia, Jennifer
    Hould, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [23] Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study
    Hendriksz, Christian J.
    Parini, Rossella
    AlSayed, Moeenaldeen D.
    Raiman, Julian
    Giugliani, Roberto
    Mitchell, John J.
    Burton, Barbara K.
    Guelbert, Norberto
    Stewart, Fiona J.
    Hughes, Derralynn A.
    Matousek, Robert
    Hawley, Sara M.
    Decker, Celeste
    Harmatz, Paul R.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : 127 - 134
  • [24] Long-term efficacy and safety profile of ezetimibe 10 mg in the treatment of patients with homozygous sitosterolemia: A multi-center, open-label, 2-year extension
    Musliner, Thomas
    Sirah, Waheeda
    Shah, Arvind
    Lin, Jianxin
    Sapre, Aditi
    Levonas, Amy Johnson
    Luetjohann, Dieter
    vonBergmann, Klaus
    CIRCULATION, 2007, 116 (16) : 93 - 93
  • [25] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10mg Nasal Spray for the Acute Treatment of Migraine
    Croop, Robert
    Madonia, Jennifer
    Hould, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Coric, Vladimir
    Lipton, Richard B.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 124 - 125
  • [26] Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
    Wells, Alvin F.
    Jia, Bochao
    Xie, Li
    Valenzuela, Guillermo J.
    Keystone, Edward C.
    Li, Zhanguo
    Quebe, Amanda K.
    Griffing, Kirstin
    Otawa, Susan
    Haraoui, Boulos
    RHEUMATOLOGY AND THERAPY, 2021, 8 (02) : 987 - 1001
  • [27] Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
    Alvin F. Wells
    Bochao Jia
    Li Xie
    Guillermo J. Valenzuela
    Edward C. Keystone
    Zhanguo Li
    Amanda K. Quebe
    Kirstin Griffing
    Susan Otawa
    Boulos Haraoui
    Rheumatology and Therapy, 2021, 8 : 987 - 1001
  • [28] LONG-TERM EFFICACY AND SAFETY PROFILE OF EZETIMIBE10MG IN TREATMENT OF PATIENTS WITH HOMOZYGOUS SITOSTEROLEMIA: A MULTI-CENTER, OPEN-LABEL, 2-YEAR EXTENSION STUDY
    Luetjohann, D.
    von Bergmann, K.
    Sirah, W.
    Shah, A.
    Lin, J.
    Sapre, A.
    Johnson-Levonas, A.
    Musliner, T.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 189 - 189
  • [29] DURABLE EFFICACY AND SAFETY OF LONG-TERM ONCE-DAILY VIBEGRON, A NOVEL ORAL β-3 ADRENERGIC RECEPTOR AGONIST: A 52-WEEK PHASE 2 STUDY IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME
    Dmochowski, Roger
    Mitcheson, David
    Frenkl, Tara
    Bennett, Nate
    Mudd, Paul N., Jr.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E970 - E971
  • [30] Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population.
    Cohen, S.
    Krishnaswami, S.
    Benda, B.
    Riese, R.
    Boy, M. G.
    Gruben, D.
    Wallenstein, G.
    Mebus, C. A.
    Zwillich, S. H.
    Bradley, J. D.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1048 - S1049
1234